Last updated on March 2019

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor


Brief description of study

The academic investigator - initiated trial will evaluate in a postapproval setting whether, and if yes, to what extent and variability, the treatment with lumacaftor in combination with ivacaftor reverses the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous subjects with cystic fibrosis under real life conditions.

Detailed Study Description

Study design. This academic investigator - initiated trial will resolve the key issue whether, and if yes, to what extent and variability, the treatment with lumacaftor in combination with ivacaftor (Orkambi) will reverse the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous subjects with cystic fibrosis under real life conditions.

Each p.Phe508del homozygous subject will function as his own control. Baseline measurements will be performed within a 4-week interval prior to the start of oral treatment with lumacaftor + ivacaftor. According to the phase 3 study results by week 4 the gain of FEV1 levels off, drug levels are in steady state and all reversible initial reductions of lung function are resolved. Thus the second assessment will be performed during the initial steady state at a day 10 - 14 weeks after the initiation of oral treatment with lumacaftor + ivacaftor. At both days of investigations the basic defect will be assessed by Gibson-Cooke pilocarpine iontophoresis sweat test, nasal transepithelial potential difference measurement (NPD) and intestinal current measurement (ICM). Moreover lung function will be measured by spirometry. The plasma concentrations of lumacaftor, ivacaftor, and their metabolites will be determined and the safety of the oral treatment with Orkambi will be assessed according to the prescribing information.

Study participants will be requested to record the administration of Orkambi by date and time for 7 days before the scheduled visit to perform functional CFTR assays. Orkambi should be administered within 30 minutes of consuming fat-containing food according to the FDA-approved patient labeling and the prescribing information. Subjects will be given a diary to record the time and doses of administration of Orkambi for seven days before the scheduled visit.

Measures against recruitment bias. The local patient databases at the three sites will be searched for all subjects who fulfil the inclusion criteria. After all subjects have been removed from the list who fulfill one or more exclusion criteria, the eligible subjects will be randomly assigned to rank numbers. Subjects will then be contacted in the sequence as they appear in the rank number list.

Statistical analysis. The sample size estimate is based on the absolute change from baseline of the cumulative chloride secretory ion current response to forskolin/IBMX and carbachol in ICM as outcome measure of CFTR function. Assuming a nominal type I error of 0.05 and a power of 0.8, 125 or 33 subjects are needed to demonstrate a treatment effect of 5% or 10%, respectively. Thus even modest changes in the basis defect can be demonstrated in a recruited cohort of 125 subjects and incomplete data sets in up to half of all subjects.

To evaluate changes in lung function and CFTR biomarkers prior and during treatment with Orkambi , Student's t test, paired Student's t test or Wilcoxon signed-rank test will be performed as appropriate. Relationships between CFTR biomarkers will be first assessed by the Pearson product-moment correlation coefficient and in case that the whole data set will be explored by canonical correlation analysis. Furthermore the sensitivity and specificity of the CFTR biomarkers in detecting treatment effects will be determined. The biostatistician from the KKS Heidelberg will assist in the statistical evaluation.

Ethical considerations. Orkambi has been approved for treatment of subjects with cystic fibrosis, homozygous for the p.Phe508del mutation. Drug handling and safety controls will be executed according to the BfArM-approved patient labeling and full prescribing information.

Study protocol and informed consent forms were approved by the ethics committees. Prior to any investigation patients and their parental guides (if applicable) will be informed about the background, objectives, schedule and assessments of the study. Each adult aged 18 years or older must sign and date the study-specific informed-consent form before any study-specific procedures can be performed. Subjects aged 12 - 17 years must assent to participate in the study and the subject's parent or legal guardian must sign and date the study-specific informed-consent form before any study-specific procedures can be performed.

Sweat test and NPD are safe procedures. Burns during iontophoresis, injuries by placement of the subcutaneous electrode for NPD or diuresis induced by swallowing of amiloride in younger subjects during nasal superfusion have not been observed at the three sites.

The collection of rectal biopsies is principally a safe and painless procedure. ICM has been performed at Hannover Medical School. since 1995. During these 20 years bleedings have been observed in five subjects one of whom required hospitalization. Haemorrhoids and abnormal bleeding times are contraindications for ICM and are exclusion criteria to participate in the study. Hence, with the exception of the low bleeding risk associated with the collection of rectal biopsies study participants are not put at risk.

There is no direct benefit for study participants, however, the decision whether or not Orkambi should be prescribed can be based on solid data.

Quality assurance. Sweat test, NPD, ICM and sampling (blood, serum, plasma) will be performed according to harmonized Standard Operating Procedures based on protocols of the Clinical Trials Network of the European Cystic Fibrosis Society and/or the Therapeutics Development Network Coordinating Center of the US Cystic Fibrosis Foundation and/or the Hannover Unified Biobank. Pre-study hands-on meetings have been organized to compare on-site the execution of the protocols including sweat test, NPD, ICM, lung function testing and sampling, processing, storage of serum and plasma specimens. Sweat testing is subject to domestic quality control trials. Local and central reading will be performed for all NPD and ICM tracings. The sites have long-standing expertise in CFTR biomarkers and have trained numerous domestic and European sites in NPD and ICM. - Subjects will be educated in drug dosing. A diary with drug dosing (date and time) will be filled out during the 7 days prior to the day of assessment.

Clinical Study Identifier: NCT02807415

Find a site near you

Start Over